Retatrutide and tirzepatide are often studied side by side because they represent successive steps in receptor breadth within the incretin research class.
The core difference
Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide is a triple agonist, adding glucagon-receptor activity to those two. That third pathway is the defining variable in comparative research.
What comparisons examine
- Receptor selectivity and relative potency across GIP, GLP-1, and glucagon
- How adding a glucagon component changes downstream signaling vs dual agonism
- Behavior in matched research models
For the receptor biology, see the incretin receptors explained. Compare with semaglutide vs tirzepatide for the single-vs-dual step.
Product pages: Retatrutide · Tirzepatide.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.